Literature DB >> 12531061

Molecular mechanisms of corticosteroid actions.

D N Payne1, I M Adcock.   

Abstract

Glucocorticoids are the most effective therapeutic agents used for the treatment of chronic inflammatory diseases of the lung. They act by interacting with, and thereby activating, a specific cytoplasmic receptor (GR) which then migrates to the cell nucleus and inhibits inflammatory gene transcription. Inflammatory gene transcription is enhanced by activation of several intracellular signalling pathways which activate transcription factor such as NF-kappaB and AP-1. These transcription factors bind to DNA and induce local unwinding of the DNA structure allowing increased gene transcription. Glucocorticoids interfere with the ability of NF-kappaB and AP-1 to induce transcription by increasing the compaction of unwound chromosomal DNA in a process that involves deacetylation of histone proteins. A small number of asthmatic patients are resistant to the beneficial effects of glucocorticoids. This defect does not appear to be due to a reduced expression of GR but may be associated with a failure of GR to translocate into the nucleus and/or a reduced ability to inhibit AP-1 actions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12531061     DOI: 10.1053/prrv.2000.0122

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  15 in total

Review 1.  Difficult asthma in children.

Authors:  S A McKenzie; A Bush
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 2.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

3.  Inflammation in the pathogenesis of lyme neuroborreliosis.

Authors:  Geeta Ramesh; Peter J Didier; John D England; Lenay Santana-Gould; Lara A Doyle-Meyers; Dale S Martin; Mary B Jacobs; Mario T Philipp
Journal:  Am J Pathol       Date:  2015-04-16       Impact factor: 4.307

Review 4.  Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?

Authors:  Lindsay J Celada; Wonder P Drake
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

5.  GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling.

Authors:  Emira Ayroldi; Ornella Zollo; Alessandra Bastianelli; Cristina Marchetti; Massimiliano Agostini; Rosa Di Virgilio; Carlo Riccardi
Journal:  J Clin Invest       Date:  2007-05-10       Impact factor: 14.808

Review 6.  Management of unresponsive asthma.

Authors:  S K Kabra; R Lodha
Journal:  Indian J Pediatr       Date:  2004-08       Impact factor: 1.967

7.  Stimulation of 11β-HSD1 expression by IL-1β via a C/EBP binding site in human fetal lung fibroblasts.

Authors:  Zhen Yang; Xiaoou Zhu; Chunming Guo; Kang Sun
Journal:  Endocrine       Date:  2009-10-06       Impact factor: 3.633

8.  Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; Keira H Skolimowska; Katalin A Wilkinson; Kerryn Matthews; Rebecca Tadokera; Anali Conesa-Botella; Ronnett Seldon; Molebogeng X Rangaka; Kevin Rebe; Dominique J Pepper; Chelsea Morroni; Robert Colebunders; Gary Maartens; Robert J Wilkinson
Journal:  Am J Respir Crit Care Med       Date:  2012-06-14       Impact factor: 21.405

9.  The glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils.

Authors:  Mirkka Janka-Junttila; Eeva Moilanen; Hannele Hasala; Xianzhi Zhang; Ian Adcock; Hannu Kankaanranta
Journal:  J Inflamm (Lond)       Date:  2006-07-12       Impact factor: 4.981

10.  Anti-inflammatory effects of dexamethasone and meloxicam on Borrelia burgdorferi-induced inflammation in neuronal cultures of dorsal root ganglia and myelinating cells of the peripheral nervous system.

Authors:  Geeta Ramesh; Olivia C Meisner; Mario T Philipp
Journal:  J Neuroinflammation       Date:  2015-12-23       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.